Thus, PPARγ deacetylation appears to be able to highlight its metabolic advantages by promoting brown fat remodeling decoupling side effects, making it possible to design safer and more efficient PPARγ agonists to treat diabetes. This evidence concerns the gene PPARG and diabetes mellitus.